College of Pharmacy

7 Greenhouse Road Kingston, RI 02881

pharmcol@etal.uri.edu – Office: 401.874.2761 Fax: 401.874.2181

URI
Think Big, We Do.
Rhode Island Seal

Chuck Wentworth, MS

pic
  • Research Associate III
  • Office: 295N
  • Phone: 401.874.9472
  • Email: chuckwentworth@uri.edu
  • Mailing Address: 7 Greenhouse Road, Kingston, RI 02881

Biography

Chuck joined the Department of Pharmacy Practice in July 2013 as a data researcher / analyst.  Chuck is working in support several funded initiatives with state agency partners to evaluate and improve medication utilization. He was formerly Research Scientist / Database Researcher with United BioSource Corporation, where he led analyses in support of pharmacoepidemiologic and health outcome studies.  Chuck has nearly 20 years of experience as a research consultant, having collaborated with numerous pharmaceutical companies, prominent research organizations and experts.  His objective is to grow our portfolio of projects in the area of pharmacoeconomics and managed care pharmacy.

 

Education

Doctoral student, Pharmacoepidemiology, University of RI

MS, Statistics, University of RI

BS, Math education / statistics, Boston University

Publications

Schneider G, Juday T, Wentworth C, Lanes S, Hebden T, Seekins D. Impact of health care payor type on HIV stage of illness at time of initiation of antiretroviral therapy in the USA. AIDS Care, 2013; published online.

Zhou X, Murugesan S, Bhullar H, Liu Q, Cai B, Wentworth C, Bate A.  An evaluation of the THIN database in the OMOP Common Data Model for active drug safety surveillance.  Drug Safety, 2013; 36(2): 119-134

Jara M, Wentworth C 3rd, Lanes S.  A new user cohort study comparing the safety of long-acting inhaled bronchodilators in COPD.  BMJ Open, 2012; 2(3).

 Arellano FM, Arana A, Wentworth C, Vidaurre C, Chipps BE. Prescription patterns for asthma medications in children and adolescents with health care insurance in the United States. Pediatric Allergy Immunology, 2011; 22(5): 469-476.

Xue F, Wentworth C, Ganesh V, Gastanaga V, Stryker S, Cha S, Zhao S. Renal impairment, hemoglobinuria, hemoglobinemia among patients with idiopathic thrombocytopenia purpura. American Journal Hematology, 2011; 86(9): 738-742.

Ambegaonkar BM, Wentworth C, Allen C, Sazonov V.  Association between extended-release niacin treatment and glycemic control in patients with type 2 diabetes mellitus: analysis of an administrative-claims database.  Metabolism, 2011; 60(7): 1038-1044

Arana A, Wentworth C, Ayuso-Mateos JL, Arellano F. Suicide-related events in patients treated with antiepileptic drugs. New England Journal of Medicine, 2010; 363: 542-551.

Arana A, Wentworth CW, Arellano FM.  Validity of the codes of suicidality in the THIN database.  Pharmacoepidemiol Drug Safety, 2010;19(12):1316-1317

 Arana A, Wentworth C, Fernandez-Vidaurre C, Schlienger RG, Conde E, Arellano F. Incidence of cancer in the general population and in patients with or without atopic dermatitis in the U.K. British Journal of Dermatology, 2010; 163(5): 1036-1043.

Alejandro Arana, Sam Allen, Jo¨rg Burkowitz, Valerio Fantoni, Ola Ghatnekar, Marı´a Teresa Rico, Nathalie Vanhaverbeke, Charles E. Wentworth, Max Brosa and Felix M. Arellano. Infliximab Paediatric Crohn’s Disease Educational Plan A European, Cross-Sectional, Multicentre Evaluation. Drug Safety, 2010; 33 (6): 1-13

Foody JM, Sajjan SG, Hu XH, Ramey DR, Neff DR, Tershakovec AM, Tomassini JE, Wentworth C, Tunceli K.  Loss of early gains in low-density lipoprotein cholesterol goal attainment among high-risk patients.  Journal Clinical Lipidol, 2010; 4(2): 126-132

 Sazonov V, Beetsch, Phatak H, Wentworth C, Evan M. Association between dylipidemia and vascular events in patients treated with statins: Report from the UK General Practice Research Database. Atherosclerosis, 2009

Arellano FM, Arana A, Wentworth C, Fernandez-Vidaurre C, Schlienger RG, Conde E. Lymphoma among patients with atopic dermatitis and/or treated with topical immunosuppressants in the United Kingdom. Journal of Clinical Immunology, 2009; 125(3): 1111-1116.

Chandwani S, Wentworth C, Burke TA, Patterson TF. Utilizatin and dosage patterns of echinocandins for treatment of fungal infections in US hospital practice. Curr Med Re Opin, 2009; 25(2): 385-393

Phatak H, Wentworth C, Sazonov V, Burke T.  Prevalence and predictors of lipid abnormalities in patients treated with statins in the UK general practice. Atherosclerosis, 2009; 202(1): 225-233

Arellano FM, Yood MU, Wentworth CE, Oliveria SA, Rivero E, Arana A, Rothman KJ.  Use of cyclo-oxygenase 2 inhibitors (COX-2) and prescription non-steroidal anti-inflammatory drugs (NSAIDS) in UK and USA populations. Pharmacoepidemiology Drug Safety, 2008;17(10):1037

 Phatak H, Wentworth C, Burke T. Lipid testing among patients beginning statin therapy in general practice in the United Kingdom. Value Health, 2008 Sep-Oct; 11(5): 933-938

Kamal-Bahl S, Burke T, Watson D, Wentworth C. Dosage, titration, and gaps in treatment with extended release niacin in clinical practice. Current Medical Research and Opinion, 2008; 30 (6): 1819-1823

Thomas A. Burke, Miriam C. Sturkenboom, Pamela A. Ohman-Strickland, Charles E. Wentworth, George G. Rhoads. The effect of antihypertensive drugs and drug combinations on the incidence of new-onset type-2 diabetes mellitus. Pharmacoepidemiology and Drug Safety. Published Online: 2 Jul 2007

Jara M, Lanes S, Wentworth C, May C, Kesten S. Comparative Safety of Long-Acting Inhaled Bronchodilators. Drug Safety, 2007; 30 (12): 1151-1160

Arellano FM, Wentworth C, Arana A, Fernandez C, Paul C. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. Journal of Investigative Dermatology, 2007; 127: 808-816.

Kamal-Bahl SJ, Burke T, Watson D, Wentworth C.  Discontinuation of lipid modifying drugs among commercially insured United States patients in recent clinical practice. Am J Cardiol, 2007; 99(4): 530-4

 Arellano FM, Yood M, Wentworth C, Oliveria S, Rivero E, Verma A, Rothman K. Use of cyclo-oxygenase 2 inhibitors (COX-2) and prescription non-steroidal anti-inflammatory drugs (NSAID) in UK and USA populations. Implications for COX-2 cardiovascular profile. Pharmacoepidemiology and Drug Safety 2006; 15: 861-872

Keston S, Jara M, Wentworth C, Lanes S. Pooled Clinical Trial Analysis of Tiotropium Safety. Chest, 2006; 130: 1695-1703

Burke TA, Sturkenboom MC, Lu S, Wentworth CE, Lin Y, Rhoads GG. Discontinuation of antihypertensive drugs among newly diagnosed hypertensive patients in UK general practice. J Hypertens 2006; 24: 1193–1200

Zhao SZ, Wentworth C, Burke TA, Makuch RW. Drug Switching Patterns Among Patients With Rheumatoid Arthritis and Osteoarthritis Using COX-2 Specific Inhibitors and Non Specific NSAIDs. Pharmacoepidemiology and Drug Safety 2004, 13(5): 277-287

Rothman KJ, CE Wentworth. Mortality of cystic fibrosis patients receiving tobramycin solution for inhalation. Epidemiology 2003, 14(1): 55-59

Osterhaus, J, C May, T Burke, CE Wentworth. Physician-reported management of edema and destabilized blood pressure in COX-2 specific inhibitor users with OA and treated hypertension. Clinical Therapeutics, 2002; volume 24, number 6 (969-989)

Johnson ES, SF Lanes, CE Wentworth, MH Satterfield, BL Abebe, LW Dicker. A metaregression analysis of the dose-response effect of aspirin on stroke. Archives of Internal Medicine, 1999; 159: 1248-1253

Lanes SF, JE Garrett, CE Wentworth, JM Fitzgerald, JP Karpel. The effect of adding nebulized ipratropium bromide to salbutamol (albuterol) in the treatment of acute asthma: a pooled analysis of three trials. Chest, 1998; 114: 365-372

Lanes SF, LL Lanza, CE Wentworth. Risk of emergency care, hospitalization, and ICU stays for acute asthma among recipients of salmeterol. American Journal of Respiratory and Critical Care Medicine, 1998; 158: 857-861

 

Copyright © 2014 University of Rhode Island.

The University of Rhode Island
Think Big, We Do.
A-ZDirectoryContact UsJump to top